Veriheal

AUGUST 21, 2023

million in gifts in support of several causes, including the promotion of arts, Lyme and tick-borne disease research, protection of the environment, and, in this case, psychedelics research. to advance scientific research into the potential therapeutic benefits of psychedelics for mental health and well-being.

Therapy 95

Therapy Research and Development Treatment Environment 95

Cannabis Law Report

MAY 31, 2023

Marijuana Moment reports The Nevada Senate has approved a bill that would create a new working group to study psychedelics and develop a plan to allow regulated access for therapeutic purposes, sending it to the Assembly for consideration.

Access 52

Access Research and Development Legislation Legalization 52

The Cannigma

JULY 1, 2022

Research funding is also up, and all of this data influences how we see, think and hear about the plant and its effects. The cannabis research problem. Despite the massive amount of research publications that come out year over year, many of these studies face one or more research design limitations.

Research and Development 108

Research and Development Data THC Clinical Trials 108

Veriheal

JANUARY 31, 2023

The obvious reasons for choosing the illicit market over the legal market include the likes of easier accessibility and lower cost. However, Clement states that the manner in which they operate is “actually what should be the models for business development in this industry.” But what about the risks that come with illicit cannabis?

Legalization 104

Legalization Research and Development Business Cannabis 104

Cannabis Law Report

FEBRUARY 5, 2022

Senior Associate, David Hardstaff and Partner, John Binns of BCL Solicitors LLP , explore the UK’s doomed Medical Cannabis (Access) Bill. For UK-based patients struggling to access much needed cannabis-based medicines, it has been difficult to be heard over the white noise of the daily news cycle. Barriers to patient access.

Access 52

Access Research and Development Medicine Patients 52

Cannabis Law Report

AUGUST 15, 2021

Aims to support acceleration of clinical development of low-dose psilocybin in SUNHA and 5MeO-DMT in other neuro-psychiatric indications. The progress Beckley Psytech has made in attracting exceptional talent to the team and advancing our ambitious clinical development programmes over the past two years has been tremendously exciting.

Medicine 98

Medicine Research and Development Conditions Treatment 98

Cannabis Law Report

AUGUST 17, 2022

Ohio State Legal Studies Research Paper No. According to its sponsors and supporters, the Safe and Fair Enforcement (‘SAFE’) Banking Act would help address the challenges faced by small cannabis businesses that cannot currently access banking services or loans. Ohio State Legal Studies Research Paper No. Cat Packer.

Banking 98

Banking Access Research and Development Compliance 98

NewsMunchies

JULY 10, 2023

Artificial intelligence is a smarter, faster, and more effective pathway to drug development. With the promise of lower costs and shorter development timelines, AI-enabled drug discovery holds major potential to increase the accessibility of drugs and to treat diseases and conditions.

Treatment 58

Treatment Research and Development Pharmaceutical Microdosing 58

Veriheal

APRIL 11, 2022

federal government is granting a handful of American companies the option to cultivate and study cannabis for medical research purposes. Groff North America is proud to be producing research-grade marijuana, so we can continue growing the field of cannabis-based medicine,” reads an official statement from the company’s website.

Pharmaceutical 104

Pharmaceutical Research and Development DEA Clinical Trials 104

Cannabis Law Report

DECEMBER 5, 2021

The Multidisciplinary Association for Psychedelic Studies (MAPS) and Vine Ventures have announced the creation of a novel, social impact Special Purpose Vehicle (SPV), called the Regenerative Financing Vine (RFV), that will infuse $70 million into patient access infrastructure and research for MDMA-assisted therapy for PTSD.

Therapy 52

Therapy Access Research and Development Clinical Trials 52

Cannabis Law Report

JANUARY 6, 2022

Oregon’s developing psilocybin program is nothing short of revolutionary and provides an opportunity to investigate the potential of psilocybin in treating a myriad of mental health conditions. An especially worrisome development is the efforts of pharmaceutical companies to patent psilocybin products. By Brett Mulligan.

Access 52

Access Patients Research and Development Treatment 52

Cannabis Law Report

DECEMBER 22, 2021

We appreciate the ongoing support received from the Canadian government through NSERC as we continue to drive this important research forward,” said Mark Upsdell, CEO, Rapid Dose Therapeutics. “We

Research and Development 52

Research and Development Events Access Pharmaceutical 52

Cannabis Law Report

MAY 29, 2022

is a Canadian company that researches, develops and grows psilocybin-producing mushrooms and functional mushrooms. A new cultivation facility that is hoping to change lives with psychedelic mushrooms had their grand opening on Friday in Princeton, after being awarded a dealer’s license in February by Health Canada.

Research and Development 52

Research and Development Clinical Trials Medicine Access 52

Cannabis Law Report

MAY 12, 2022

The new tool lets individual users and businesses connect with the entire Canxchange universe through a public chat feature, and gives them instant access to the company’s sales and support team. Under a limited access “light” version users can network and access data. Two options.

Access 52

Access Research and Development Hemp Data 52

Americans for Safe Access

MAY 25, 2021

You will also find out how to access the recorded panels from Unity 2021 to catch anything you missed. Information on research steps from NIDA and DEA, House progress on SAFE Banking and other key bills, Developments in Alabama and Mississippi a call to action for veterans and a profile of ASA's 2021 Researcher of the Year, Philippe Lucas.

Research and Development 148

Research and Development DEA Banking Access 148

Cannabis Law Report

JULY 6, 2021

This collaboration is intended to include research into COMP360 psilocybin therapy and other novel therapies that may be developed by COMPASS in areas of unmet need such as depression, post-traumatic stress disorder (PTSD) and anorexia.

Research and Development 98

Research and Development Clinical Trials Therapy Patients 98

Veriheal

NOVEMBER 30, 2021

Veriheal does not support illegally consuming therapeutic substances such as psilocybin but acknowledges that it transpires because of the current illicit status, which we strive to change by advocating for research, legal access, and responsible consumption. Unfortunately, tobacco is easy to access and addiction is hard to curb.

Research and Development 98

Research and Development Therapy Data Treatment 98

Veriheal

MARCH 17, 2022

However, new research has found that psychedelic use is only “weakly associated with psychosis-like symptoms.” New Research Published on Serotonergic Psychedelic Use and Psychosis. New Research Published on Serotonergic Psychedelic Use and Psychosis. The research team under the leadership of Alexander V.

Research and Development 98

Research and Development Therapy Conditions History 98

Cannabis Law Report

MAY 29, 2022

Earlier this month, Senators Brian Schatz (D-HI) and Cory Booker (D-NJ) sent a letter to the National Institutes of Health (NIH) and the Food and Drug Administration (FDA) urging both agencies to advance research on the therapeutic effects of psychedelic drugs. [1] Recent Regulatory Developments. Challenges.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

JULY 28, 2021

This direct access to patients and clinics is expected to differentiate KGK from other CROs by providing the opportunity to study patients with differing demographics across various populations, while also shortening recruitment timelines for studies.

Clinical Trials 81

Clinical Trials Research and Development Treatment Therapy 81

Cannabis Law Report

MARCH 9, 2022

This license expansion will further position Numinus as a recognized global research centre for natural psychedelic medicines, and supplements the current work Numinus is already undertaking on Psilocybe species and inherent synergistic compounds. Harmaline and harmalol naturally occur in B. caapi , while P. viridis , D.

Research and Development 52

Research and Development Therapy Access Medicine 52

Cannabis Law Report

MAY 14, 2022

One of the largest and arguably sustainable customer bases, however, is consumers with some sort of health or therapeutic need for which they are unable to access medicinal cannabis. One potential consequence of the FSA’s drive to rein in the UK’s CBD industry is reduced access to the previously available wide range of products.

Access 52

Access CBD Research and Development Medicine 52

Cannabis Law Report

AUGUST 19, 2021

Agreement allowing work on numerous collaborative research initiatives in the coming years. The Johns Hopkins Behavioral Pharmacology Research Unit has extensive experience conducting clinical research related to therapeutic use of psychedelics. DENVER, Aug. Johnson, Ph. About Mydecine Innovations Group.

Medicine 98

Medicine Research and Development Therapy Pharmaceutical 98

Cannabis Law Report

JANUARY 31, 2022

TSX-V:NUMI, OTC:LKYSF) said that its research facility– Numinus Bioscience– has been included on Health Canada’s list of federally licensed psilocybin producers. This list is available by request to those seeking access to psilocybin through the Special Access Program (SAP), and clinical researchers.

Research and Development 52

Research and Development Clinical Trials Packaging Access 52

Puff Puff Post

JANUARY 24, 2019

“There were times when I was told you couldn’t even use ‘cannabis’ and ‘research’ in the same sentence,” he recalled. which is conducting millions of dollars worth of research on the use of cannabis to treat conditions including anxiety, insomnia and pain. The federal government is investing in marijuana research too.

Research and Development 111

Research and Development Legalization Marijuana Recreational 111

Cannabis Law Report

SEPTEMBER 14, 2021

Mr Morris will be advising COMPASS on research related to new psychedelic compounds that could be developed into therapies in areas of unmet mental health need. Mr Morris will be advising COMPASS on research related to new psychedelic compounds that could be developed into therapies in areas of unmet mental health need.

Research and Development 52

Research and Development Therapy Pharmaceutical History 52

Cannabis Law Report

JUNE 28, 2021

Together we want to advance the development of high-quality medicinal cannabis and have made it our mission to improve the quality of life of neurological patients who still have symptoms despite conventional therapy. ” “Supporting therapies, like medical cannabis, are a meaningful addition to Zambon’s European portfolio. “As

Access 105

Access Research and Development Pharmaceutical Therapy 105

Cannabis Law Report

AUGUST 20, 2022

CRCC’s paper, published by the Ohio State University (OSU) Moritz College of Law, is titled “Not a SAFE Bet: Equitable Access to Cannabis Banking, An Analysis of the SAFE Banking Act.”. Ohio State Legal Studies Research Paper No. But unfortunately, SAFE, as written, is unlikely to result in equitable access to financial services.

Banking 52

Banking Access Research and Development Policy 52

SpeedWeed

AUGUST 16, 2021

Oxford-based startup Beckley Psytech in the United Kingdom announced August 15 that it raised $80 million to ramp up clinical trials and research using a pharmaceutical formulation of ??5-MeO-DMT From Psychedelic Toad Venom to Medical Research. View original article.

Research and Development 52

Research and Development Clinical Trials Treatment Conditions 52

Cannabis Law Report

JULY 29, 2021

Scientists and researchers do not know exactly how or why these negative results occur, but they are still working on the question. The Ehave Infinity Portal offers a powerful machine learning and artificial intelligence platform with a growing set of advanced tools and applications developed by Ehave and its leading partners.

Research and Development 105

Research and Development Conditions Data Patients 105

Cannabis Law Report

APRIL 13, 2022

Delic Labs’ latest exemptions enable the Company to develop innovative analytical methods for psychedelic research. Last year, the lab also applied for a Dealer’s License with the intent of commercializing psilocybin research and associated intellectual property (IP) for medical and research purposes.

Research and Development 52

Research and Development Treatment Extraction Medicine 52

Cannabis Law Report

MAY 12, 2022

Beckley Psytech to collaborate with Lophora on researching New Clinical Entities (NCE’s). Under the terms of the agreement Beckley Psytech will jointly fund continuing development of the Lophora pipeline and collaborate broadly on R&D. Beckley Psytech has been working diligently to build a first-class drug development capability.

Medicine 52

Medicine Research and Development Clinical Trials Treatment 52

Veriheal

FEBRUARY 14, 2024

The board will work on projects like designing the training program for psychedelic facilitators, tracking psychedelic policy development, studying ongoing science related to psilocybin, and making recommendations to lawmakers regarding the bill. People will not have to meet specific qualifications to access care.

Therapy 62

Therapy Legalization Research and Development Treatment 62

Cannabis Law Report

JULY 8, 2021

The study is the first of its kind and will be conducted within Swinburne’s Drugs and Driving Research unit, which is led by Professor Downey. ‘We We are grateful for this grant, and especially for the opportunity to further our research in this space,’ says Professor Downey. ‘It Medicinal Cannabis Research Collaboration (MCRC).

Medicine 98

Medicine Research and Development Safety THC 98

Cannabis Law Report

AUGUST 30, 2021

The goal of the research is to provide a foundation for the discovery and characterization of additional sources of genetic resistance to the various pathogens that infect C. Mihalyov, PhD and Oregon CBD Director of Research & Development Andrea R. Authors included Dewey Scientific Co-Founder Paul D. Garfinkel, PhD.

Research and Development 103

Research and Development Sativa Agriculture Cultivation 103

Cannabis Law Report

FEBRUARY 28, 2022

In the past two decades, pioneering research has rekindled interest in the therapeutic use of psychedelic substances such as psilocybin, ibogaine, and dimethyltryptamine (DMT). Indigenous communities have used them for centuries, and researchers studied them in the 1950s and ‘60s. Glenn Cohen & Mason Marks. 20 February 2022.

Research and Development 52

Research and Development Therapy Law Clinical Trials 52

Cannabis Law Report

NOVEMBER 1, 2021

In the past few decades, pioneering research has rekindled interest in the therapeutic use of psychedelic substances such as psilocybin, ibogaine, and dimethyltryptamine (DMT). Indigenous communities have used them for centuries, and researchers studied them in the 1950s and 60s. Date Written: October 23, 2021. war on drugs.

Research and Development 52

Research and Development Law Clinical Trials Therapy 52